Global and China Osteoporosis Drugs Market

Global and China Osteoporosis Drugs Market, Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates, Alderonate, Risedronate, Ibandronate, Zoledronic Acid, Others, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), Global and China Osteoporosis Drugs Market (By Route Of Adinistration: Oral, Injectable, Others), Global and China Osteoporosis Drugs Market (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Osteoporosis is characterized by a decrease in the density and quality of bones, which frequently leads to broken wrist, hip, and spine bones. Various factors responsible for osteoporosis include, genetic factors; low intake of calcium, magnesium, and vitamin D; eating disorders such as anorexia, inactivity & immobility, and excessive alcohol intake. Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures). Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Market Dynamics

The increasing research & development activities are attributed to the growth of the global and China osteoporosis drugs market. For instance, according to a study shared by Contemporary OB/GYN- a monthly publication dedicated to translating science into clinical practice, on March 10, 2023, Hormone therapy (HT) for osteoporosis can increase lumbar spine bone mineral density (BMD) and prevent bone loss in post menopausal women. The large cross-sectional study showed that current and prior use of multiple types of hormone therapies, including combined hormone contraception used in premenopausal women and menopause hormone therapies, were linked with bone protection in postmenopausal women and that these effects persisted after discontinuation of treatment. The article also concluded that stopping HT and varying doses impact bone health, including fracture risk.

Key features of the study:

• This report provides an in-depth analysis of the global and China osteoporosis drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global and China osteoporosis drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck KGaA, Lilly, Procter & Gamble, Enzo Biochem Inc., Sanofi, Novartis AG, Wyeth Nutrition (A subsidiary of Pfizer Inc.), F. Hoffmann-La Roche Ltd, GSK plc, UCB S.A., Amgen Inc., BeiGene, Inc., Bone Biologics Corp, TEIJIN LIMITED, Eden Biologics (Formerly known as JHL Biotech Inc.), Keros Therapeutics, and Taro Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global and China osteoporosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global and China osteoporosis drugs market.

Detailed Segmentation:

• Global and China Osteoporosis Drugs Market, By Drug Type:
• Bisphosphonates

Alendronate

Risedronate

Ibandronate

Zoledronic Acid

Others

• Calcitonin
• Hormone Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
• Rank Ligand (RANKL) Inhibitor
• Global and China Osteoporosis Drugs Market, By Route of Administration:
• Oral
• Injectable
• Others
• Global and China Osteoporosis Drugs Market, By Distribution Channel:
• Hospitall Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Global and China Osteoporosis Drugs Market, By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Company Profiles
• Merck KGaA
• Lilly
• Procter & Gamble
• Enzo Biochem Inc.
• Sanofi
• Novartis AG
• Wyeth Nutrition (A subsidiary of Pfizer Inc.)
• F. Hoffmann-La Roche Ltd
• GSP plc
• UCB S.A.
• Amgen Inc.
• BeiGene, Inc.
• Bone Biologics Corp
• TEIJIN LIMITED
• Eden Biologics (Formerly known as JHL Biotech Inc.)
• Keros Therapeutics
• Taro Pharmaceutical Industries Ltd.